

July 27, 2017

The Listing Department,
BSE Limited (BSE)
P. J. Towers, Dalal Street,
Mumbai- 400 001

The Listing Department,
National Stock Exchange of India Ltd. (NSE)
Exchange Plaza, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai- 400 051

Scrip ID-540025

Scrip Code-ADVENZYMES

Dear Sir,

Subject: Intimation of execution of agreement to acquire shares of a company based in Germany by wholly-owned subsidiary of the Company
Ref: ISIN: INE837H01020

The Company's wholly owned subsidiary, Advanced Enzymes Europe B.V. based in Amsterdam (Netherlands) has signed a Definitive Agreement dated July 26, 2017 with evoxx technologies GmbH, a company based in Germany ("Evoxx") and all the shareholders of Evoxx to acquire 100% shareholding (i.e. 164,031 shares) in Evoxx for a total consideration of Euro 7.65 Million. The acquisition is expected to be completed by mid of August 2017.

On completion of the aforesaid acquisition, Evoxx will become direct subsidiary of Advanced Enzymes Europe B.V. and indirect subsidiary of Advance Enzyme Technologies Limited.

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 are as follows:

Sr. No.	Particulars	Status / Remarks
a)	Name of the target entity, details in brief such as size, turnover etc.;	Name: evoxx technologies GmbH (Evoxx) Turnover: Euro 3 Million approx. Present Nominal share capital: Euro 164,031.00 consisting of 164,031 of Euro 1.00 each



b)	<p>Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?</p> <p>If yes, nature of interest and details thereof and whether the same is done at "arm's length"</p>	<p>Evoxx is not a related party of the Advanced Enzymes Europe BV / Company.</p> <p>None of promoter/promoter group/group companies have any interest in Evoxx.</p>
c)	Industry to which the entity being acquired belongs	Development & production of enzymes & certain nutritional carbohydrates
d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Expansion of business in Europe and strengthening of Research & development capabilities.
e)	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable as the acquisition is being done by the Company's wholly owned subsidiary in Netherlands
f)	Time period for completion of the acquisition	Is expected to be completed by mid of August 2017.
g)	Nature of consideration	Cash
h)	Cost of acquisition or the price at which the shares will be acquired	Euro 7.65 Million
i)	Percentage of shareholding / control acquired and / or number of shares acquired	100% shareholding to be acquired by Advanced Enzymes Europe BV, a wholly owned subsidiary of the Company, based in Netherlands.
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Date of Incorporation: September 07, 2016. Evoxx was formed on this date as a result of merger of evocatal GmbH (formed in 2006) and aevotis GmbH (formed in 2009). evocatal GmbH, an entity registered in Germany first acquired aevotis GmbH and then through a merger process incorporated Evoxx.



SS

		<p>Country of Incorporation: Germany</p> <p>Any other country in which Evoxx has presence – Europe, India and China.</p> <p>Turnover: Euro 3 Million approx.</p> <p>Evoxx is engaged in development & production of enzymes & certain nutritional carbohydrates.</p>
--	--	--

This is for your information and for public at large.

Thanking you,

Yours Faithfully,

For Advanced Enzyme Technologies Limited



Sanjay Basantani
Company Secretary and Head – Legal

